Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2023-10-05 Interim / Quarterly Rep…
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive business and earnings update for the first half of 2023. It includes detailed financial tables (balance sheet, income statement) for the period ending June 30, 2023, and provides extensive management commentary on clinical trials, strategy, and governance. Although it mentions that the full half-year financial report would be published separately, the document itself contains substantive financial data and analysis, qualifying it as an Interim/Quarterly Report (IR) rather than a mere announcement. H1 2023
2023-10-05 English
NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023
Earnings Release Classification · 100% confidence The document is titled "NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023" and explicitly states that the financial results for the first semester of 2023 (January 1 to June 30, 2023) were approved by the Board of Directors on October 5, 2023. It contains a detailed table of social accounts comparing the 6 months ended June 30, 2023, with previous periods. This structure—a comprehensive financial report covering a period shorter than a year (six months)—fits the definition of an Interim / Quarterly Report (IR). Although it mentions the 'rapport financier semestriel sera mis à disposition du public le 6 octobre 2023', the provided text *is* the content of that report, not just the announcement of its publication, making IR the correct classification over RPA. H1 2023
2023-10-05 French
NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL TRIAL REVEALING A PROLONGED EFFECT FOR NFL-101 AND MODIFICATION OF THE STRATEGY FOR COMMUNICATING THE CESTO II STUDY RESULTS
Earnings Release Classification · 95% confidence The document is a press release from NFL Biosciences announcing promising results from the PRECESTO clinical trial regarding their drug NFL-101, and simultaneously announcing a strategic modification to the reporting timeline for the CESTO II trial results (delaying publication until July 2024). This type of announcement, detailing key operational and clinical updates, is characteristic of an Earnings Release (ER) or a general press release that often accompanies financial reporting periods. Since it focuses heavily on clinical trial results and strategic updates rather than being a full financial report (10-K or IR), and it is an initial announcement of results, 'ER' (Earnings Release) is the most appropriate classification, especially as the text mentions the decision will be announced in connection with the 'half-year earnings press release'. It is not a transcript (CT), a formal regulatory filing (RNS), or a management discussion (MDA), but rather the primary announcement of operational news. Q4 2023
2023-09-25 English
NFL BIOSCIENCES : RESULTATS PROMETTEURS DE L'ETUDE CLINIQUE PRECESTO REVELANT UN EFFET PROLONGE DE NFL-101 ET MODIFICATION DE LA STRATEGIE DE COMMUNICATION DES RESULTATS DE L’ETUDE CESTO II
Earnings Release Classification · 95% confidence The document is a press release from NFL Biosciences announcing promising results from the PRECESTO clinical study regarding their drug NFL-101, and simultaneously announcing a proposed change in the communication strategy for the ongoing CESTO II study results (delaying communication until July 2024 to maintain blinding for full 12-month data utilization). This type of announcement, detailing clinical trial outcomes and strategic updates, is characteristic of an Earnings Release (ER) or a general press release related to operational/financial performance highlights. Since it focuses on key results and strategic decisions rather than being a full, comprehensive report (like an IR or 10-K) or a transcript, 'ER' (Earnings Release) is the most appropriate classification for summarizing key periodic business developments, even though it's not strictly tied to a quarterly earnings report date, but rather a major operational update. The document is relatively long (9261 chars), suggesting it contains more than just a brief announcement, but it is structured as a formal update to the market. Q3 2023
2023-09-25 French
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE BREVET AUX ÉTATS-UNIS DÉDIÉE À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL AVEC NFL-301 & PRÉPARATION D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA
Regulatory Filings Classification · 96% confidence The document is a press release from NFL Biosciences announcing two key corporate actions: 1) The filing of a patent application in the US related to their drug candidate NFL-301 for alcohol consumption reduction, and 2) The preparation for a pre-IND submission to the FDA. This content relates to intellectual property protection and regulatory/development pipeline updates. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a formal shareholder vote result (DVA). Since it is an announcement detailing progress on drug development, IP, and regulatory steps, it fits best under the general category of corporate/regulatory news that doesn't fit a more specific financial or governance code. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-financial, non-governance corporate news, although 'LTR' (Legal Proceedings Report) is sometimes used for IP/regulatory actions, RNS is a better general fit for pipeline updates that aren't formal SEC filings or specific legal reports. However, since the core announcement is about a patent filing and FDA preparation, which are critical regulatory/development milestones, and it is presented as a press release, RNS is the most suitable general regulatory announcement category.
2023-07-18 French
Nfl Biosciences: Patent Application Filed in the United States for Reducing Alcohol Consumption With Nfl-301 & Preparation of a Pre-Ind Application Submission With the Fda
Regulatory Filings Classification · 95% confidence The document is an announcement from NFL Biosciences detailing the filing of a patent application in the United States for its drug candidate NFL-301, which aims to reduce alcohol consumption. It also mentions the preparation for a pre-IND application submission with the FDA. This type of announcement, focusing on intellectual property strategy (patent filing) and regulatory preparation (pre-IND), does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific corporate development update related to drug development and legal protection. Since it is not a standard financial report, a management change, or a dividend notice, and it concerns a specific corporate action/update, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general regulatory/corporate update, or potentially 'Capital/Financing Update' (CAP) if the IP is viewed as a key asset development, but RNS is a better fit for specific, non-financial regulatory/IP news that isn't covered elsewhere. Given the focus on patent filing and FDA preparation, it is a significant corporate event announcement. I will classify it as RNS as it is a specific regulatory/IP announcement that doesn't match the other specific categories.
2023-07-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.